Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium as Add-on to Personalized Maintenance ECT for Preventing Depression Relapse
NCT06751875Completed
- Sponsor
- University of Antwerp
- Start
- Jul 2019
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of lithium in major depressive disorder (MDD) (2 arms), sponsored by University of Antwerp. Primary endpoint: Relapse Rate at 6 months. Started Jul 2019; status: completed.
02
Drugs
lithium
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06751875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751875.